https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-547
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2022-03-10 / Ther Apher Dial 2022 Jun;26(3):537-5472022-03-10 00:00:002022-03-10 00:00:00Wilms‘ tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-03-03 / Clin Transl Immunology 2020;9(3):e1117
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-03-03 / Clin Transl Immunology 2020;9(3):e11172020-03-03 00:00:002020-03-03 00:00:00Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-06-22 / Cancers (Basel) 2019 Jun;11(6)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-06-22 / Cancers (Basel) 2019 Jun;11(6)2019-06-22 00:00:002019-06-22 00:00:00Can Dendritic Cell Vaccination Prevent Leukemia Relapse?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-04-27 / J Clin Med 2019 Apr;8(5)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-04-27 / J Clin Med 2019 Apr;8(5)2019-04-27 00:00:002019-04-27 00:00:00Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-690
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-03-03 / Br. J. Haematol. 2019 May;185(4):679-6902019-03-03 00:00:002019-07-01 09:16:10Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-02-19 / Cancer Sci. 2019 Mar;110(3):849-857
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-02-19 / Cancer Sci. 2019 Mar;110(3):849-8572019-02-19 00:00:002019-07-01 08:21:29Maintenance of long remission in adult T-cell leukemia by Tax-targeted vaccine: A hope for disease-preventive therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-12-05 / Blood Rev. 2019 03;34:67-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-12-05 / Blood Rev. 2019 03;34:67-832018-12-05 00:00:002018-12-05 00:00:00Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-1518
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-07-23 / Cancer Immunol. Immunother. 2018 Oct;67(10):1505-15182018-07-23 00:00:002019-02-15 08:32:52A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-325
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-15 / Blood Rev. 2018 Jul;32(4):312-3252018-02-15 00:00:002019-02-15 08:32:43Anti-cancer vaccine therapy for hematologic malignancies: An evolving era
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2018-02-08 / JCI Insight 2018 Feb;3(3)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2018-02-08 / JCI Insight 2018 Feb;3(3)2018-02-08 00:00:002019-02-15 08:32:51Efficacy of intracellular immune checkpoint-silenced DC vaccine
